Balancing symptoms and side effects is difficult when treating patients with schizophrenia. New approaches to treatment and new therapies in the pipeline offer hope for this difficult-to-treat mental health disorder.
Side effects from medication have the greatest impact on adherence for patients with Schizophrenia. They lower quality of life, daily functioning, and satisfaction.
Negative symptoms contribute to poor functional outcomes in schizophrenia. Evaluating different symptom domains and understanding the disorder’s reward circuitry can help with intervention and patients’ leading more fulfilling lives.
Schizophrenia affects 1% of the world’s population largely during a patient’s most productive years. Multiple treatments are available, however many gaps to recovery exist. Learn from experts diagnostic criteria for and defining recovery in schizophrenia.
Drs Anderson and Malone cover the types of dementia and their indicators, ways to approach care for mild cognitive impairment (MCI) and mild dementia, and treatment options available or in the pipeline for disease intervention. Early diagnosis and intervention of MCI and mild dementia can slow disease progression and optimize outcomes for both patients and caregivers.
Drs Anderson and Malone discuss the burden of, signs and symptoms of, diagnostic tools and criteria for mild cognitive impairment (MCI) and mild/early dementia and the benefits of early diagnosis. Early diagnosis and intervention of MCI and mild dementia can slow disease progression and optimize outcomes for both patients and caregivers.
This video reviews treatment guidelines for patients with DMD and emphasizes the importance of clinicians intervening early on behalf of individuals who develop behavioral-psychosocial comorbidities.
How to screen UACR and eGFR levels, implement selective non-steroidal MRA therapies, and mitigate the risk of hyperkalemia to prevent CKD disease progression
Prompt treatment of early-stage Alzheimer disease (AD) can curb symptom progression. Tests for biomarkers, new symptomatic treatments and disease-modifying agents, and the addition of the preclinical stage to AD diagnostic criteria can aid in earlier disease recognition and building treatment plans.
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.

Pages

Subscribe to RSS - Patient/Physician Communication